✦ LIBER ✦

Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis

✍ Scribed by Beuselinck, Benoit; Lerut, Evelyne; Wolter, Pascal; Dumez, Herlinde; Berkers, Johannes; Van Poppel, Hendrik; Joniau, Steven; Oyen, Raymond; De Wever, Liesbeth; Strijbos, Michiel; Paridaens, Robert; Schöffski, Patrick

Book ID: 121974680
Publisher: CIG Media Group, LP.
Year: 2014
Tongue: English
Weight: 163 KB
Volume: 12
Category: Article
ISSN: 1558-7673
DOI: 10.1016/j.clgc.2014.04.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of vascular endothel

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features

✍ Jae-Lyun Lee; Inkeun Park; Kwonoh Park; Seongjoon Park; Yongcheol Ahn; Jin-Hee A 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 317 KB

Clinical factors associated with outcome

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

✍ Toni K. Choueiri; Jorge A. Garcia; Paul Elson; Mohamad Khasawneh; Saif Usman; Al 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract ## BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF) pathway is a standard of care for patients with metastatic renal cell carcinoma (RCC). The identification of patients who are more likely to benefit from these agents is warranted. ## METHODS. In to

A “Game of Thrones” in Metastatic Renal

A “Game of Thrones” in Metastatic Renal Cell Carcinoma: Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors and Mammalian Target of Rapamycin Inhibitors Battling for Position

✍ Pal, Sumanta Kumar; Vogelzang, Nicholas J. 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 471 KB

Effects of combined valproic acid and th

Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro

✍ Eva Juengel; Johanna Engler; Ausra Mickuckyte; Jon Jones; Lukasz Hudak; Dietger 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 509 KB

Can Tyrosine Kinase Inhibitors be Discon

Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis

✍ Manfred Johannsen; Anne Flörcken; Axel Bex; Jan Roigas; Marco Cosentino; Vincenz 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 539 KB

Activity of SU11248, a Multitargeted Inh

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

✍ Kibel, A.S.; Ornstein, D.K.; Finley, D.S. 📂 Article 📅 2007 🏛 Elsevier Science ⚖ 61 KB